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Abstract
Background—Given the lack of promptness and inevitable use of additional contrast agents, the 
myocardial viability imaging procedures have not been used widely for determining the need to 
performing revascularization.
Objective—This study is aimed to evaluate the feasibility of myocardial viability assessment, 
consecutively with diagnostic invasive coronary angiography (ICA) without use of additional 
contrast agent, using a novel hybrid system comprising ICA and multislice CT (MSCT).
Methods—In all, 14 Yucatan miniature swine models (female; age, 3 months; weight, 28–30 kg) 
were subjected to ICA followed by balloon occlusion (90 minutes) and reperfusion of the left 
anterior descending coronary artery. Two weeks after induction of myocardial infarction, delayed 
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hyperenhancement (DHE) images were obtained, using a novel combined machine comprising 
ICA and 320-channel MSCT scanner (Aquilion ONE, Toshiba), after 2, 5, 7, 10, 15, and 20 
minutes after conventional ICA. The heart was sliced in 10-mm consecutive sections in the short-
axis plane and was embedded in a solution of 1% triphenyltetrazolium chloride (TTC). Infarct size 
was determined as TTC-negative areas as a percentage of total left ventricular area. On MSCT 
images, infarct size per slice was calculated by dividing the DHE area by the total slice area (%) 
and compared with histochemical analyses.
Results—Serial MSCT scans revealed a peak CT attenuation of the infarct area (222.5 ± 36.5 
Hounsfield units) with a maximum mean difference in CT attenuation between the infarct areas 
and normal myocardium of at 2 minutes after contrast injection (106.4; P for difference = 0.002). 
Furthermore, the percentage difference of infarct size by MSCT vs histopathologic specimen was 
significantly lower at 2 (8.5% ± 1.8%) and 5 minutes (9.5% ± 1.9%) than those after 7 minutes. 
Direct comparisons of slice-matched DHE area by MSCT demonstrated excellent correlation with 
TTC-derived infarct size (r = 0.952; P < .001). Bland-Altman plots of the differences between 
DHE by MSCT and TTC-derived infarct measurements plotted against their means showed good 
agreement between the 2 methods.
Conclusion—The feasibility of myocardial viability assessment by DHE using MSCT after 
conventional ICA was proven in experimental models, and the optimal viability images were 
obtained after 2 to 5 minutes after the final intracoronary injection of contrast agent for 
conventional ICA.
Keywords
Multislice computed tomography; Myocardial viability; Myocardial contrast delayed; 
enhancement
1. Introduction
A dysfunctional myocardium can be characterized by 3 separate entities: stunning, 
hibernation, and scar.1,2 Within this spectrum, the differentiation of scar from stunning or 
from hibernation is essential for future prognosis, as stunning and hibernating myocardium 
are considered reversible with appropriate revascularization treatment.3–5 Various imaging 
modalities including stress echocardiography, single-photon emission CT, positron emission 
tomography, and magnetic resonance imaging (MRI) have been used to discriminate viable 
and nonviable myocardium.6,7 Of these modalities, delayed hyperenhancement (DHE) 
imaging using MRI has been proven to be the most reliable in the detection of myocardial 
scar.8–11 Given iodine-based contrast has similar kinetics to that based on gadolinium,12 
there has been some attempt in using multislice CT (MSCT) for DHE imaging.13,14 
Furthermore, MSCT has demonstrated excellent correlation with DHE of MRI and 
histopathologic specimens.15 However, viability imaging of the myocardium has not been 
used extensively for determining the need to perform revascularization—primarily because 
viability imaging including MSCT cannot be performed simultaneously alongside invasive 
coronary angiography (ICA). As such, patients typically undergo coronary revascularization 
as a secondary procedure several days after undergoing viability imaging, which can be 
Jang et al. Page 2









time-consuming and impractical, and the patient may also be prone to potential side effects 
from the use of additional intravenous contrast agents.16
Recently, Sato et al demonstrated that myocardial viability imaging using DHE by MSCT 
could be obtained immediately after percutaneous coronary intervention (PCI) without 
additional use of intravenous contrast.17 A drawback of that study, however, was that 
patients’ cardiac MSCT scans were performed after coronary revascularization; hence, these 
study findings are not applicable for determining coronary revascularization. Nevertheless, 
these observations imply that DHE imaging by MSCT after ICA without additional contrast 
use may be useful in overcoming some of the current limitations surrounding viability 
imaging. In this investigation, we therefore studied the feasibility of myocardial viability 
assessment, concurrent with diagnostic ICA, for the guidance of coronary revascularization 
using a novel hybrid system comprising ICA and MSCT.
2. Materials and methods
2.1. Animal model preparation
The study complied with the regulations of the animal care committee of the Cardiovascular 
Product Evaluation Center, Yonsei University, and the National Institutes of Health 
publication of “The 1996 Guide for the Care and Use of Laboratory Animals.”18 In all, 14 
Yucatan miniature swine models (female; age, 3 months; weight, 28–30 kg) were enrolled 
for the present study. The pigs were initially sedated with tiletamine and zolazepam (Zoletil 
50; Virbac, Carros, France) 5 mg/kg and xylazine (Rompun; Bayer Korea, Seoul, South 
Korea) 2 mg/kg and then intubated. Anesthesia was maintained with 1% to 1.5% isoflurane 
in 100% oxygen gas at a flow of 1.5 mL/minute and administered by the anesthesia machine 
with mechanical ventilation (Primus; Drager, Lubeck, Germany). Adequate anesthesia was 
confirmed by the absence of a limb withdrawal reflex. Monitoring by limb-lead 
electrocardiography (ECG) was performed throughout the operation with polygraph. Before 
procedures, ketorolac (5 mg/kg) was administered intramuscularly to relieve pain and 
prevent inflammation. This protocol was used for the creation of myocardial infarction, ICA, 
and MSCT image acquisitions.
2.2. Creation of myocardial infarction
The experimental swine model was placed in a dorsal recumbency, and the incision site was 
prepared aseptically with standard Betadine (Betadine, Korea Pharma, Seoul, Korea) and 
alcohol scrub. Fifteen minutes before balloon occlusion, all swine received 300-mg 
amiodarone to lower the risk of ventricular fibrillation. After placement of a 6F introducer 
sheath in the right carotid artery by surgical cut down, each animal received a single dose of 
heparin (200 U/kg) and bretylium tosylate (2.5 mg/kg). Under fluoroscopic guidance 
(INFX-8000V; Toshiba), a 6F Judkins left guiding catheter (Cordis; Johnson and Johnson) 
was positioned in the left coronary ostium. After the intracoronary administration of 
nitroglycerin (200 μg), coronary angiography was determined by cine-radiography to 
demonstrate left anterior descending (LAD) artery patency (Fig. 1). A 3.0 × 15-mm 
angioplasty balloon (Medtronic) was then positioned immediately distal to the first diagonal 
LAD vessel and inflated to normal pressure, which was dependent on its compliance chart to 
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achieve vessel occlusion for a period of 90 minutes, followed by reperfusion. Animals were 
monitored until full recovery and then were returned to housing.
2.3. Imaging data acquisition for MSCT after conventional ICA
Two weeks after inducing myocardial infarction, ICA and MSCT were performed. Swine 
were anesthetized as described previously. Coronary angiography and acquisition of MSCT 
viability imaging were performed using a novel cardiovascular interventional therapeutic CT 
(CVIT-CT) system, which allowed for the acquisition of coronary angiography and MSCT 
consecutively (Fig. 2). Before ICA procedures, a noncontrast MSCT image was obtained for 
the purpose of acting as a control. For ICA procedures, a CVIT-CT system was set to 
coronary angiography mode. To mimic clinical ICA procedures, routine coronary 
angiography images for the left coronary artery were obtained in right anterior oblique 
caudal, right anterior oblique cranial, anterior-posterior cranial, left anterior oblique cranial, 
and left anterior oblique caudal views, as well as anterior-posterior caudal. A total of 24 mL 
(4 mL per each view) contrast agent (Iomeron 400 mg/mL; Bracco, Milan, Italy) was 
injected intracoronary during routine ICA. After obtaining the ICA images, the CVIT-CT 
system was switched to MSCT acquisition mode. MSCT images were acquired using a 
prospective ECG-gated 320-channel scanner (Aquilion ONE; Toshiba Medical Systems, 
Otawara, Japan) with the following characteristics: collimation and slice thickness, 0.5 mm; 
reconstruction increment, 0.3 mm; reconstruction field of view, 109 to 123 mm; 
reconstruction kernel, FC43; reconstruction algorithm, adaptive iterative dose reduction 3D; 
tube rotation time, 0.35 seconds; tube voltage, 120 kVp; current, 550 mA; and prospective 
ECG gating, 75% R-R interval. We assessed intracoronary-injected contrast agent kinetics 
by tracking signal intensity of the infarct region and remote myocardial region (adjacent left 
ventricular free wall and mid-ventricular septum) over a duration of 20 minutes. To explore 
the contrast wash-in and wash-out kinetics and determine optimal image acquisition timing 
for DHE after intracoronary contrast injection by time delay between contrast injection and 
MSCT image acquisition, all MSCT scans were performed at 2, 5, 7, 10, 15, and 20 minutes 
after last intracoronary contrast injection, and each image was compared with 
histopathologic specimens. Reconstructed images were then transferred to a commercially 
available workstation (Vitrea fX 6.4; Toshiba Medical Systems, Otawara, Japan) for 
subsequent analyses.
2.4. Histopathologic specimen preparation and interpretation
The heart was removed immediately after image acquisition for sectioning and staining. The 
heart was sliced in 10-mm consecutive sections in the short-axis plane. To obtain a viability 
staining, sliced myocardia were embedded in 1% of 2, 3, 5-triphenyltetrazolium chloride 
(TTC) solution (Sigma-Aldrich; St. Louis, MO) at 37° C for 15 minutes, followed by 
fixation in a buffered 4.5% formalin solution for 20 minutes. For histopathologic specimen 
analysis, all slices showing myocardial scar by TTC staining were digitally photographed for 
further investigation. Infarct size was defined as TTC-negative area by hand planimetry for 
each myocardial slice and expressed as an area ratio (%) for each section using ImageJ 
platform (ImageJ version 1.36b; National Institutes of Health, Bethesda, MD). The area of 
myocardial infarction of the histopathologic specimen was measured independently from 
MSCT images.
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2.5. Image data analysis
For MSCT image analyses, multiplanar reconstructions of axial slices were coregistered 
using anatomic landmarks by an independent investigator who did not further participate in 
MSCT analysis (Fig. 3).13,19–21 Thereafter, 2 experienced readers, who were level III 
equivalent and/or board certified in cardiovascular CT,22 were blinded to histopathologic 
specimen results, analyzed the MSCT images. To quantify infarct size in each matched 
short-axis slice, the endocardial and epicardial contours of the left ventricle and the contours 
of the delayed enhancement were manually measured repeatedly. Mean values from those 
measurements were used for further calculations. The presence of an infarct size in an 
MSCT image was defined as the delayed enhancement area for each matched short-axis 
slice and expressed as a percentage of the area of the total left ventricular wall at each slice. 
The percentage difference in infarct size by MSCT compared with histopathologic specimen 
at each time point was defined as the difference between the infarct size in MSCT and 
histopathologic specimen divided by the infarct size by a histopathologic specimen.
2.6. Statistical methods
For the MSCT images, the interobserver reliability in the measurement of the infarct size 
was assessed by means of the intraclass correlation coefficient (2-way random, single 
measure).23 The CT attenuation differences between infarct tissue and remote normal 
myocardium at each time point were compared using paired t test. The infarct size 
measurement errors of MSCT over time were compared using repeated measures 1-way 
analysis of variance with Bonferroni correction for post hoc analyses. The agreement and 
correlation between infarct size assessed with MSCT and histopathology were evaluated 
with Bland-Altman analysis and the Pearson correlation coefficient, respectively. All tests 
were 2-sided, and P < .05 was regarded as statistically significant. Statistical analyses were 
performed using SAS (version 9.2; SAS Institute Inc., Cary, NC).
3. Results
Among 14 swine models, 2 pigs expired because of persistent ventricular fibrillation during 
the creation of a myocardial infarction. Thus, multidetector CT images and histopathologic 
images were obtained in a total of 12 pigs.
3.1. Optimal image acquisition timing for DE imaging after CAG
As illustrated in Fig. 4, myocardial delayed scan images were obtained serially at 2, 5, 7, 10, 
15, and 20 minutes. MSCT identified a peak CT attenuation of the infarct area (222.5 ± 36.5 
HU) and normal myocardium (116.1 ± 45 HU; Fig. 3A and B), with a maximum mean 
difference in CT attenuation between the infarct areas and normal myocardium of 106.4 at 2 
minutes after contrast injection (P for difference = 0.002). Contrasts were subsequently 
washed out and the attenuation difference between infarct and normal myocardium was 
decreased to 65.7 ± 23.6 HU at 5 minutes (P for difference compared with normal 
myocardium = 0.003). The statistical significance of differences in CT attenuation between 
infarct area and remote normal myocardium was observed up until 15 minutes after the last 
intracoronary contrast injection.
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We calculated the percentage difference in infarct size by MSCT compared with 
histopathologic specimen at each time point between 2 and 20 minutes to investigate the 
accuracy of MSCT infarct measures over time (Fig. 5). Mean percentage difference in 
infarct size by MSCT appeared to increase with time from the last intracoronary contrast 
injection to the MSCT image acquisition (P = .035, repeated measurement analysis of 
variance). Compared with the mean percentage difference at 2 minutes (8.5% ± 1.8%), the 
mean percentage difference at 5 minutes (9.5% ± 1.9%) did not differ materially (P = .580). 
However, the mean percentage differences vs histopathologic specimen increased 
significantly from 7, 10, 15, and 20 minutes (eg, 24.1% ± 8.2%, 30.0% ± 13.3%, 25.2% ± 
17.4%, and 59.9% ± 12.7%, respectively) when compared with 2-minute postintracoronary 
contrast injection (all P < .05).
3.2. Comparison of the size of hyperenhanced regions on MSCT and TTC-stained area of 
histopathologic specimen
On the basis of the previously mentioned study findings and also considering the feasibility 
in the clinical setting to allow transition time from ICA to MSCT acquisition, we used the 
infarct measurement result at 5 minutes to test for further agreement between MSCT and 
histopathologic specimens. Interobserver variability for identification of infarct size between 
2 experienced readers for MSCT images was intraclass correlation coefficient = 0.93 (95% 
confidence interval, 0.87–0.97). Direct comparisons of reconstructed slice-matched DHE 
area measured by MSCT after ICA demonstrated excellent correlation with TTC-derived 
infarct size in histopathologic specimens (r = 0.952; 95% confidence interval, 0.904–0.976; 
P < .001; Fig. 6A). Finally, Bland-Altman plots of the difference between DHE by MSCT 
and TTC-derived infarct measurements plotted against their means (Fig. 6B) demonstrated 
good agreement between the 2 methods.
4. Discussion
In this experimental study involving swine models, we set out to determine the feasibility of 
myocardial viability assessment by ascertainment of delayed-enhancement MSCT after 
conventional ICA without additional contrast agent use. The major finding was that 
myocardial viability assessment using DHE area measured by MSCT between 2- and 5-
minute duration after conventional ICA displayed excellent agreement with infarct size as 
measured by histochemical staining.
The importance of a viability assessment using various imaging modalities for determination 
of revascularization treatment is well documented.24,25 Given the available data, current 
guidelines suggest viability evaluation in patients with left ventricular dysfunction and who 
are known to be amenable to revascularization is appropriate.26 As a surprise, however, 
viability imaging has not been widely used in the clinical setting. One plausible explanation 
for its lack of use in the clinical setting to date is that it has remained a challenge to conduct 
viability imaging simultaneously with ICA. Current procedures after diagnosis of 
obstructive coronary artery disease by ICA indicate patients should undergo the following 
costly and time-consuming steps: (1) being discharged from the catheterization laboratory; 
(2) waiting for scheduling a viability imaging test; (3) undergoing a viability test; (4) 
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waiting for the viability imaging results; and (5) if necessary, revisiting the catheterization 
laboratory to undergo a secondary revascularization procedure. Furthermore, another reason 
that could influence the physicians’ decision to use viability imaging for determining 
revascularization is the additional use of contrast agent required. Indeed, contrast agents 
required to perform an MSCT or MRI could expose the patient to potential risks including 
nephrotoxicity or nephrogenic systemic fibrosis.16 Although it bears mentioning, these 
potential side effects are more common in patients with renal dysfunction, which is 
prevalent in patients who are referred for viability imaging.27
Foremost, the present study demonstrates that viability assessment using a novel hybrid 
CVIT-CT system can likely overcome these limitations. On background of present study 
data, the CVIT-CT system permitted accurate viability assessment without additional 
contrast agent administration almost concurrent with ICA. Importantly, optimal viability 
images were obtained after 2 to 5 minutes after the final intracoronary injection of contrast 
agent for conventional ICA, which is fitting with prior intravenous injection viability 
studies.28 Conversely, the accuracy of viability assessment after intracoronary injection 
diminished after 7 minutes, demonstrating that the wash-out of contrast occurred at a more 
rapid rate than that observed under intravenous injection.28–30 Hence, quick acquisition (ie, 
approximately 5 minutes duration) of DHE imaging by MSCT is an important component 
for the accurate assessment of myocardial viability, especially when using the method 
described in the present study.
Moving forward, we suggested the conceptual framework (Fig. 7) that provides a stepwise, 
timed approach for image acquisition and interpretation process in patients with suspected 
coronary artery disease and severe left ventricular dysfunction. If the patient has a coronary 
artery disease on ICA, the CVIT-CT system is immediately switched to MSCT acquisition 
mode and performs a viability scan within 5 minutes. An experienced radiologist or 
cardiologist will interpret the viability scan immediately after the scan and discuss with the 
interventionalist to perform revascularization based on the integrated information of ICA 
and viability imaging. This whole process can be completed within 20 minutes, and 
coronary revascularization can be performed immediately, eliminating, in part, any 
unnecessary time delay between ICA and intervention and the potential hazard from 
additional contrast agent use of MSCT or cardiac MRI. Forthcoming studies are needed to 
fully address the clinical utility, safety, and efficacy of this novel protocol.
5. Limitations
The present study only included subacute (2 weeks) experimentally produced infarcts in 
swine models. Thus, the feasibility of the current imaging acquisition protocol in an 
emergency coronary intervention or chronic myocardial infarction setting (ie, >2 weeks) 
remains to be determined. In addition, the present study was performed using reopened 
arteries at the time of contrast injection and MSCT image acquisition. In the clinical 
myocardial infarction setting, the artery may be closed at the time of contrast injection, and 
the enhancement quality and timing may differ. Forthcoming studies aimed at exploring the 
contrast kinetics and delayed-enhancement qualities in obstructed arteries appear necessary. 
Finally, given the design and nature of the present study protocol, myocardial viability 
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imaging could not be acquired between 0 and 2 minutes after administration of the contrast 
agent. Additional studies investigating the wash-in and wash-out kinetics of intracoronary 
contrast administration are required.
6. Conclusion
In the current investigation, the feasibility of myocardial viability assessment by DHE using 
MSCT after conventional ICA was proven in an experimental swine model. Forthcoming 
studies are now warranted to address the safety, utility, and validity of concurrent ICA and 
MSCT within the clinical setting.
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Representative invasive coronary angiography images acquired before, during, and after 
balloon injury (white arrow) for creation of myocardial infarction.
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Schematic illustration (A) and actual image (B) of a novel cardiovascular interventional 
therapeutic CT system for a consecutive acquisition of invasive coronary angiography and 
myocardial viability imaging by multislice CT.
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Examples of comparisons of histopathologic specimens and multislice CT images on the 4 
swine models (A-D). The black and white arrows indicate TTC-stained area on 
histopathologic specimen and hyperenhanced regions on MSCT respectively.
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Time course of CT attenuation (Hounsfield unit [HU]) (A) in myocardial infarct (MI) tissue 
and remote normal myocardium (normal) and example of short-axis images (B) after 
intracoronary injection of iodine contrast for conventional invasive coronary angiography.
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The percentage difference in infarct size by multislice CT (MSCT) compared with 
histopathologic specimen at each time point after intracoronary contrast injection for 
conventional invasive coronary angiography.
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The correlation (A) and Bland-Altman analyses (B) of infarct sizes assessed by 
histopathologic specimen and multislice CT (MSCT).
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Conceptual framework of viability assessment using a cardiovascular interventional 
therapeutic CT system in a patient with suspected coronary artery disease and severe left 
ventricular dysfunction. ICA, invasive coronary angiography.
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